|
1
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Friedman HS, Prados MD, Wen PY, et al:
Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH,
Yao XH, Gao L, Wang JM and Bian XW: Isolation and characterization
of cancer stem cells from a human glioblastoma cell line U87.
Cancer Lett. 265:124–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sherry MM, Reeves A, Wu JK and Cochran BH:
STAT3 is required for proliferation and maintenance of multipotency
in glioblastoma stem cells. Stem Cells. 27:2383–2392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Villalva C, Martin-Lannerée S, Cortes U,
Dkhissi F, Wager M, Le Corf A, Tourani JM, Dusanter-Fourt I, Turhan
AG and Karayan-Tapon L: STAT3 is essential for the maintenance of
neurosphere-initiating tumor cells in patients with glioblastomas:
a potential for targeted therapy? Int J Cancer. 128:826–838. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang YP, Chang YL, Huang PI, et al:
Resveratrol suppresses tumorigenicity and enhances radiosensitivity
in primary glioblastoma tumor initiating cells by inhibiting the
STAT3 axis. J Cell Physiol. 227:976–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohno M, Natsume A, Kondo Y, Iwamizu H,
Motomura K, Toda H, Ito M, Kato T and Wakabayashi T: The modulation
of microRNAs by type I IFN through the activation of signal
transducers and activators of transcription 3 in human glioma. Mol
Cancer Res. 7:2022–2030. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ivanov SV, Salnikow K, Ivanova AV, Bai L
and Lerman MI: Hypoxic repression of STAT1 and its downstream genes
by a pVHL/HIF-1 target DEC1/STRA13. Oncogene. 26:802–812. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamura T, Sato S, Haque D, Liu L, Kaelin
WG Jr, Conaway RC and Conaway JW: The Elongin BC complex interacts
with the conserved SOCS-box motif present in members of the SOCS,
ras, WD-40 repeat, and ankyrin repeat families. Genes Dev.
12:3872–3881. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dasari VR, Kaur K, Velpula KK, Gujrati M,
Fassett D, Klopfenstein JD, Dinh DH and Rao JS: Upregulation of
PTEN in glioma cells by cord blood mesenchymal stem cells inhibits
migration via downregulation of the PI3K/Akt pathway. PLoS One.
5:e103502010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frew IJ, Thoma CR, Georgiev S, Minola A,
Hitz M, Montani M, Moch H and Krek W: pVHL and PTEN tumour
suppressor proteins cooperatively suppress kidney cyst formation.
EMBO J. 27:1747–1757. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bar EE: Glioblastoma, cancer stem cells
and hypoxia. Brain Pathol. 21:119–129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu B, Sun X, Zhang D, Wang Y, Tao J and
Ou S: TRAIL and paclitaxel synergize to kill U87 cells and
U87-derived stem-like cells in vitro. Int J Mol Sci. 13:9142–9156.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada H, Dezawa M, Shimazu S, Baba M,
Sawada H, Kuroiwa Y, Yamamoto I and Kanno H: Transfer of the von
Hippel-Lindau tumor suppressor gene to neuronal progenitor cells in
treatment for Parkinson’s disease. Ann Neurol. 54:352–359.
2003.PubMed/NCBI
|
|
16
|
Hägerstrand D, He X, Bradic Lindh M, Hoefs
S, Hesselager G, Ostman A and Nistér M: Identification of a
SOX2-dependent subset of tumor- and sphere-forming glioblastoma
cells with a distinct tyrosine kinase inhibitor sensitivity
profile. Neuro Oncol. 13:1178–1191. 2011.
|
|
17
|
Kanno H, Kuwabara T, Shinonaga M, Chang
CC, Tanaka Y, Sugio Y, Morita H, Yasumitsu H, Umeda M and Nagashima
Y: Establishiment of a human glioma cell line bearing a
homogeneously staining chromosomal region and releasing α- and
β-type transforming growth factors. Acta Neuropathol. 79:30–36.
1989.PubMed/NCBI
|
|
18
|
Yamada S, Kanno H and Kawahara N:
Trans-membrane peptide therapy for malignant glioma by use of a
peptide derived from the MDM2 binding site of p53. J Neurooncol.
109:7–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bleau AM, Hambardzumyan D, Ozawa T,
Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt
pathway regulates the side population phenotype and ABCG2 activity
in glioma tumor stem-like cells. Cell Stem Cell. 4:226–235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maxwell PH, Wiesener MS, Chang GW,
Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and
Ratcliffe PJ: The tumour suppressor protein VHL targets
hypoxia-inducible factors for oxygen-dependent proteolysis. Nature.
399:271–275. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanno H, Shuin T, Kondo K, Yamamoto I, Ito
S, Shinonaga M, Yoshida M and Yao M: Somatic mutations of the von
Hippel-Lindau tumor suppressor gene and loss of heterozygosity on
chromosome 3p in human glial tumors. Cancer Res. 57:1035–1038.
1997.PubMed/NCBI
|
|
22
|
Sun X, Liu M, Wei Y, Liu F, Zhi X, Xu R
and Krissansen GW: Overexpression of von Hippel-Lindau tumor
suppressor protein and antisense HIF-1alpha eradicates gliomas.
Cancer Gene Ther. 13:428–435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Valk PE, Mathis CA, Prados MD, Gilbert JC
and Budinger TF: Hypoxia in human gliomas: demonstration by PET
with fluorine-18-fluoromisonidazole. J Nucl Med. 33:2133–2137.
1992.PubMed/NCBI
|
